Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29674864 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HDAC1HDAC6CA1CA9 | |
| SCHEMBL113484 | 0.84 | ALDH1A1 (0.48) | ALDH1A1HDAC1HDAC6CA1CA9 | |
| SCHEMBL9391171 | 0.78 | MAPT (0.43) | ALDH1A1HDAC1HDAC6CA1CA9 | |
| SCHEMBL29674966 | 0.78 | MAPT (0.43) | ALDH1A1HDAC1HDAC6CA1CA9 | |
| SCHEMBL418340 | 0.78 | MAPT (0.43) | ALDH1A1HDAC1HDAC6CA1CA9 | |
| SCHEMBL114114 | 0.77 | ALDH1A1 (0.48) | ALDH1A1HDAC1CA1CA9CA2 | |
| SCHEMBL9154640 | 0.74 | ALDH1A1 (0.46) | ALDH1A1HDAC1CA1CA9CA2 | |
| SCHEMBL231997 | 0.72 | CA1 (0.39) | ALDH1A1HDAC1HDAC6CA1CA9 | |
| SCHEMBL104581 | 0.72 | ERN1 (0.46) | ALDH1A1HDAC1CA1CA9CES2 | |
| SCHEMBL21118245 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805805-B | Polyimide with high adhesive strength and preparation method and application thereof | 深圳先进电子材料国际创新研究院 | 2023-12-19 | — | — | CN | claimed |
| CN-114805805-A | Polyimide with high bonding strength and preparation method and application thereof | 中国科学院深圳先进技术研究院 | 2022-07-29 | — | — | CN | claimed |
| CN-114573805-A | Preparation method of high-barrier transparent flame-retardant copolymerized nylon | 浙江恒逸石化研究院有限公司 | 2022-06-03 | — | — | CN | claimed |
| US-12492185-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2025-12-09 | — | — | US | disclosed |
| EP-3952866-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TEIJIN PHARMA LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025021868-A1 | TRAF2 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2025-01-30 | — | — | WO | disclosed |
| EP-3697410-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TEIJIN PHARMA LTD (JP) | 2024-12-18 | — | — | EP | disclosed |
| CN-115960352-B | Photosensitive polyimide precursor resin, preparation method thereof and photosensitive resin composition | 深圳市道尔顿电子材料股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118108680-A | Preparation method and application of alkyl sulfonyl benzimidazole compound | 广东方中高新材料有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240158385-A1 | NOVEL COMPOUNDS | Cerevance, Inc. | 2024-05-16 | — | — | US | disclosed |
| CN-114096247-B | Benzimidazole derivatives and uses thereof | 帝人制药株式会社 | 2024-04-26 | — | — | CN | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| EP-1305308-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002008224-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1117651-A1 | NEW BIS-BENZIMIDAZOLES | Bayer Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020401-A1 | NEW BIS-BENZIMIDAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492185-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPC4, TRPC3 | ALDH1A1 1414/4885HDAC1 1395/4885HDAC6 152/4885 |
| US-20240158385-A1 | NOVEL COMPOUNDS | KCNK3, KCNA4, KCNK13 | ALDH1A1 2143/4885HDAC1 1304/4885HDAC6 2149/4885 |
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | ALDH1A1 1654/4885HDAC1 1231/4885HDAC6 2364/4885 |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | ABCB11, ATP1A2, ATP1A1 | ALDH1A1 426/4885HDAC1 770/4885HDAC6 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.